Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)
Nathan, Ascierto, Haanen, Espinosa, Demidov, Garbe, Guida, Lorigan, Chiarion-Sileni, Gogas, Maio, Fierro, Hoeller, Terheyden, Gutzmer, Guren, Bafaloukos, Rutkowski, Plummer, Waterston, Kaatz, Mandala, Marquez-Rodas, Muñoz-Couselo, Dummer, Grigoryeva, Young, Schadendorf (2019) Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172) Eur J Cancer (IF: 8.4) 119 168-178Links
http://www.ncbi.nlm.nih.gov/pubmed/31445199http://dx.doi.org/10.1016/j.ejca.2019.07.010
